NOVANTA INC 8-K

Summary

Q3 2026 results with Q4 and FY guidance. Revenue rose 23% Y/Y, including $32.9M from acquisitions, while management cited continued customer momentum.

Q4 revenue guidance midpoint is $309M, +1.3% Q/Q from $305M; adjusted EBITDA midpoint is $77.5M vs $80.3M, and adjusted diluted EPS midpoint is $0.94 vs $1.05, with EPS growth guided to 0%-5% Y/Y vs +20.7% in Q3. For FY2026, reported revenue growth guidance was raised to 16% from at least 15%, while adjusted diluted EPS guidance was lowered to $3.66-$3.71 from $3.68-$3.74; the company also expects reported revenue growth above 15% in FY2027.

Developments

• Customer bookings increased 29% and backlog reached $543M, which management described as a foundation for future growth.
• Riverpoint Medical, acquired during the quarter, is performing in line with expectations; Novanta cited progress on operational synergies and a new product pipeline.

Results with guidance

Metric	Guided for Q3 2026	Q3 2026 actual	9M 2026	Q4 2026 guide	FY2026 guide
Revenue	$300M-$304M	$305M (beat)+23% Y/Y, +15% Q/Q	—	$306M-$312M+1.3% Q/Q at midpoint (better than reported)	$1.135B-$1.140Bnarrowed from $1.13B-$1.14B
Operating cash flow	—	$39.3M+363% Y/Y, -39% Q/Q	$156M+182% Y/Y	—	$200M
Adjusted EBITDA (non-GAAP)	$74M-$77M	$80.3M (beat)+38% Y/Y, +32% Q/Q	—	$76M-$79M-3.5% Q/Q at midpoint (worse than reported)	$274M-$277Mnarrowed from $273M-$278M
Adjusted Diluted EPS (non-GAAP)	$0.95-$1.00	$1.05 (beat)+21% Y/Y, +18% Q/Q	—	$0.91-$0.96-11% Q/Q at midpoint (worse than reported)	$3.66-$3.71lowered from $3.68-$3.74
Reported revenue growth	—	—	—	at least 18% growth Y/Y	16% growth Y/Yraised from at least 15% growth Y/Y
Adjusted Diluted EPS growth (non-GAAP)	—	—	—	0%-5% growth Y/Yvs 20.7% Y/Y in Q3 2026	11%-13% growth Y/Ylowered from at least 12% growth Y/Y
Adjusted EBITDA growth (non-GAAP)	—	—	—	—	at least 24% growth Y/Yreaffirmed from at least 24% growth Y/Y

Earlier guidance from the 8-K filed 2026-08-05.

Results without guidance

Metric	Q3 2026	Change
Operating income	$13.9M	-36% Y/Y, -23% Q/Q
Net income	$2.02M	-81% Y/Y, -84% Q/Q
Diluted EPS	$0.05	-83% Y/Y, -83% Q/Q
Capital expenditures	$8.97M	+109% Y/Y, +20% Q/Q
Free Cash Flow (non-GAAP)	$31.5M	+648% Y/Y, -45% Q/Q
Cash and cash equivalents	$149M	-79% Q/Q
Total debt	$830M	+261% Q/Q
Gross margin	44.5%	-0.3 pp Y/Y, -1.0 pp Q/Q
Adjusted Gross Profit Margin (non-GAAP)	47.0%	+0.5 pp Y/Y, -0.1 pp Q/Q
Diluted shares	42.7M	+19% Y/Y, +3.8% Q/Q

What moved the numbers

• Organic Revenue Growth (non-GAAP), which excludes acquisitions and foreign currency effects, was 9.9%.
• Automation Enabling Technologies revenue was $145M vs $125M Y/Y, with GAAP gross margin of 50.2% vs 47.3%; Medical Solutions revenue was $160M vs $123M, with GAAP gross margin of 39.9% vs 43.0%.
• The largest adjustments between GAAP and non-GAAP results included $21.4M of intangible-asset amortization and $19.2M of acquisition and related costs.
• Cash paid for the acquisition, net of working-capital adjustments, was $1.20B; borrowings under senior credit facilities were $626M.

Other guidance (2)

Metric	Period	Guidance
Reported revenue growth	FY2027	at least 15% growth Y/Y
Organic Revenue Growth (non-GAAP)	FY2026	7% growth Y/Y

Figures extracted from the filings and checked against their text; changes and verdicts computed from them.